Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-04.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 88 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 89
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Copyright © 2017 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.
Age, yr | Prevalence of hypercholesterolemia, %a | ||
---|---|---|---|
Total | Male | Female | |
≥30b | 19.5 | 16.9 | 22.1 |
30–49 | 12.1 | 14.7 | 9.4 |
50–64 | 24.5 | 18.1 | 30.9 |
≥65 | 30.3 | 20.8 | 37.6 |
Age, yr | Prevalence of hypertriglyceridemia, %a | ||
---|---|---|---|
Total | Male | Female | |
≥30b | 16.8 | 23.9 | 10.4 |
30–49 | 17.3 | 27.5 | 7.9 |
50–64 | 17.9 | 24.1 | 12.2 |
≥65 | 13.9 | 14.9 | 13.0 |
Values are expressed as percentage.
aAwareness: proportion of the population diagnosed by a doctor; bAll over 30 years old; cTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; dRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; eRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.
Values are expressed as mean±standard error.
KNHANES, Korean National Health and Nutrition Examination Survey.
aAwareness: proportion of the population diagnosed by a doctor; bTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; cRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; dRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.